Tosoh Launches Contract Business for Abnormal Cell Analysis in Blood

Tokyo, Japan—Tosoh Corporation has established analysis technologies for the detection of abnormal cells in the blood and the analysis of cancer-related gene mutations in such cells. In June 2019, Tosoh Analysis and Research Center Co., Ltd. headquartered in Shunan City Yamaguchi Prefecture, launched a contract abnormal cell analysis business through which these technologies will be applied. The new business will serve research institutes and pharmaceutical companies hoping to apply the results in their research.

The following bio-related technologies will be applied through the contract analysis business:

  • Technology to safely preserve blood samples (prevents blood sample degradation during transport)

  • Technology to separate abnormal cells from the majority red blood cells and white blood cells

  • Technology to align and capture cells on a microfabricated chip using dielectrophoresis

  • Technology to detect abnormal cells using anti-C45 antibodies, anti-cytokeratin (CK) antibodies, and nuclear staining agent DAPI

  • Technology for imaging abnormal CK-negative cells based on size and other aspects

Using model samples spiked with human lung carcinoma cell line H1975, these technologies could detect more than 80% of spiked cells as abnormal cells.  Additionally, in analyzing cancer-related gene mutations, it is possible to analyze the presence of 50 cancer-related genes in the  retrieved abnormal cells using a commercially available gene analysis panel.

Furthermore, the new contract analysis business has the technology to be able to detect both abnormal CK-positive and abnormal CK-negative cells. This will contribute to progress in research into the correlation between the number of CK-positive and CK-negative cells and cancer metastasis.

Meanwhile, Tosoh is proceeding with the development of technologies to separate and detect a variety of cells and molecules. Once the technologies are verified, Tosoh Analysis and Research Center will gradually expand the contract cell analysis business, targeting research institutes and pharmaceutical companies. It will also accelerate research and development activity in its search for marker molecules useful in detecting specific diseases as well as non-invasive and minimally invasive detection technologies. And, through the development of applications in the diagnostic and healthcare fields, it will contribute to helping people live healthy lives. 

Analysis Items

  • Counting abnormal CK-positive and CK-negative cells in the blood (number of cells/mL of blood)

  • Analyzing mutations in 50 oncogenes and cancer suppressor genes

NOTE 1: These results of the analysis are for research use only and cannot be used for medical, diagnostic or therapeutic use on human beings or animals.

NOTE 2: The services provided by the contract business is only available to customers in Japan. 

Overview of Tosoh Analysis and Research Center Co., Ltd.

Established:       October 1999
Business:  Chemical substance and environment-related analysis and inspection
Ownership:  Tosoh Corporation 100%


TOSOH CORPORATION

Who We Are

Tosoh is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people and generated net sales of ¥861.5 billion (US$7.8 billion at the average rate of ¥110.9 to the US dollar) in fiscal 2019, ended March 31, 2019.

What We Do

Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh’s petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future in part by manufacturing a variety of eco-products.

Stock Exchange Ticker Symbol: 4042

Disclaimer

This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. Forward-looking statements are identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the results expressed in forward-looking statements.

For more information, please contact

 

Jeff Markley
International Corporate Development
Tosoh Corporation

jeff.markley@tosoh.com
Tel: +81 3 5427 5118
Fax: +81 3 5427 5198